Monoclonal antibodies have been developed against circulating bombesin and one such antibody 2A11 has been shown to inhibit the growth of SCLC in vitro and as xenografts in nude mice (Chaudhry et al, 1999); however, it has limited efficacy in human trials. Here, GRP is linked to small cell lung carcinoma.